Results 61 to 70 of about 1,559,737 (159)

Preserflo MicroShunt versus Trabeculectomy: Efficacy and Surgical Success within a Heterogenous Patient Cohort

Life
To compare success rates of trabeculectomy (TE) and Preserflo MicroShunt (PMS) in heterogenous glaucoma cohorts with regards to different pre- and postoperative therapeutic regimens.
Lynn Anna Barbara Zweifel, Jens Julian Storp, Friederike Elisabeth Vietmeier, Moritz Fabian Danzer, Ralph-Laurent Merté, Nicole Eter, Viktoria Constanze Brücher   +6 more
doaj   +1 more source

Prospective, Non-randomized, 36-Month Study of Second-Generation Trabecular Micro-Bypass Stents with Phacoemulsification in Eyes with Various Types of Glaucoma

Ophthalmology and Therapy, 2018
Introduction The aim of this study was to assess 36-month outcomes after cataract surgery and implantation of two second-generation trabecular micro-bypass stents (iStent inject, Glaukos Corporation, San Clemente, CA, USA) into eyes with predominantly ...
Fritz H. Hengerer, Gerd U. Auffarth, Christoffer Riffel, Ina Conrad-Hengerer   +3 more
doaj   +1 more source

Management of Steroid-Induced Glaucoma in a Patient with Pyoderma Gangrenosum

, 2023
Pyoderma gangrenosum (PG) is an uncommon inflammatory skin disorder typically presenting as painful skin ulcers, which may also exhibit extracutaneous findings. PG can occur at the site of trauma or surgery, which is known as the pathergic phenomenon.
Young Kook Kim, Ji Yeon Byun, Yong Hyun Jang, Yong Koo Kang, Dai Woo Kim   +4 more
core   +1 more source

Real-world Case Series of iStent or iStent inject Trabecular Micro-Bypass Stents Combined with Cataract Surgery

Ophthalmology and Therapy, 2019
Introduction This real-world retrospective case series assessed 12-month effectiveness and safety following implantation of iStent® or iStent inject ® trabecular micro-bypass with cataract surgery.
David Manning
doaj   +1 more source

Minimally Invasive Glaucoma Surgery (MIGS): an updated literature review

, 2022
Glaucoma is considered the biggest cause of irreversible blindness in the world and the increase in intraocular pressure is its main risk factor. Usually, the initial therapy for glaucoma consists of reducing IOP through the instillation of topical ...
Emílio Rintaro Suzuki Júnior (13826653), Alberto Diniz-Filho (802622), Felipe Leão de Lima (13826650)   +2 more
core   +1 more source

Minimally Invasive Glaucoma Surgery

, 2023
Glaucoma, a leading cause of irreversible vision loss worldwide, is managed by reducing intraocular pressure (IOP) using medications, lasers, or surgical procedures.
Afflitto, Gabriele Gallo, Swarup S. Swaminathan, Gabriele Gallo Afflitto, Swaminathan, Swarup S.   +3 more
core   +1 more source

Minimally invasive glaucoma surgery: current status and future prospects [PDF]

, 2016
Grace M Richter,1,2 Anne L Coleman11UCLA Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, CA, USA; 2USC Eye Institute, Department of Ophthalmology, Keck School of Medicine of University of Southern ...
Coleman AL, Richter GM, Richter, Grace M, Coleman, Anne L   +3 more
core   +1 more source

Multicenter Effectiveness and Disease Stability Through 3 Years After iStentTrabecular Micro-Bypass with Phacoemulsification in Glaucoma and Ocular Hypertension

Clinical Ophthalmology, 2022
Colin Clement,1– 4 Frank Howes,5 Alexandros Ioannidis,6 Michael Shiu,7 David Manning,8 Jed A Lusthaus,3,4,9 Simon E Skalicky,10 Todd W Goodwin11 1Eye Associates, Sydney, NSW, Australia; 2Fairfield Eye Surgery, Fairfield, NSW, Australia; 3Glaucoma Unit ...
Clement C, Howes F, Ioannidis A, Shiu M, Manning D, Lusthaus JA, Skalicky SE, Goodwin TW   +7 more
doaj  

iStent Trabecular Microbypass Stent Implantation with Phacoemulsification in Patients with Open-Angle Glaucoma: 6-Year Outcomes

Clinical Ophthalmology, 2020
Tanner J Ferguson,1 Keegan B Mechels,1 Zachary Dockter,2 Adam Bleeker,2 Mitch Ibach,3 Justin Schweitzer,3 John P Berdahl3 1Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA; 2University of South Dakota Sanford School of Medicine, Sioux Falls, SD ...
Ferguson TJ, Mechels KB, Dockter Z, Bleeker A, Ibach M, Schweitzer J, Berdahl JP   +6 more
doaj  

Long-term titrated IOP control with one, two, or three trabecular micro-bypass stents in open-angle glaucoma subjects on topical hypotensive medication: 42-month outcomes

Clinical Ophthalmology, 2018
L Jay Katz,1 Carl Erb,2 Amadeu Carceller Guillamet,3 Antonio M Fea,4 Lilit Voskanyan,5 Jane Ellen Giamporcaro,6 Dana M Hornbeak6 1Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA; 2Glaucoma Service, Eye Clinic Wittenbergplatz, Berlin, Germany;
Katz LJ, Erb C, Carceller Guillamet A, Fea AM, Voskanyan L, Giamporcaro JE, Hornbeak DM   +6 more
doaj